Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Metastatic castration-resistant prostate cancer (mCRPC) and its predecessor, metastatic hormone-sensitive prostate cancer (mHSPC) are advanced forms of the disease that do not respond to initial treatments such as surgery and hormone therapy and then begin to spread. About 12.5% of men develop prostate cancer in their lifetime, and the chance of developing prostate cancer increases with age; prostate cancer is most common in men between the ages of 65 and 74, with an average age of 67 at diagnosis. Historically, systemic therapy for metastatic and advanced prostate cancer has included androgen suppression. For metastatic disease, the median progression-free survival and overall survival of 24-36 months with this palliative treatment are 18-20 months.

Description

A more advanced form of the disease, metastatic castration-resistant prostate cancer (mCRPC), and its predecessor, metastatic hormone-sensitive prostate cancer (mHSPC), do not respond to initial therapies like surgery and hormone therapy and instead spread. towards the prostate. Prostate-specific antigen (PSA) response and clinical improvement are seen in more than 90% of patients receiving androgen deprivation therapy for advanced prostate cancer; however, this therapy is not curative, and the majority of patients eventually develop resistance to testicular development. Castration-resistant prostate cancer (CRPC) describes a diverse group of asymptomatic or asymptomatic patients with or without clinical metastases. A type of prostate cancer known as castration-resistant prostate cancer does not respond to first-line therapies such as surgery and/or the common hormone therapy known as androgen deprivation therapy (ADT). Even though mCRPC treatments can be highly successful, the disease is frequently incurable, especially if it is caught early. They are particularly difficult cases for patients and medical professionals because mHSPC and mCRPC are resistant to some treatments. At the beginning of the twenty-first century, the recommendations of the Prostate Cancer Working Group 2 (PCWG2) led to an increase in clinical trials. PTAC clearly detects prostate cancer progression despite castrated testosterone levels (andlt;0.5 ng/ml), and this progression may be biochemical, radioactive, or symptomatic. The disease has advanced forms known as metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), which do not respond to initial therapies like surgery and hormone therapy before spreading. the prostate. mCRPC differs from mHSPC in that the latter disease still responds to the common hormone therapy known as androgen deprivation therapy (ADT), despite having spread to other areas of the body. Castration-resistant forms of mCRPC in particular are extremely risky and have extremely poor prognoses. Though the precise mechanism by which one targets the other is not completely understood, mCRPCs can be broadly characterized as further proliferative and progressive mHSPCs. The persistent disease after ADT, which occurs when cancer cells spread to bones, lymph nodes, and other organs despite androgen deprivation, is a distinctive feature of this type. A worse prognosis is associated with it being a more serious and advanced form of cancer. Healthcare professionals may suggest a digital rectal exam or a blood test for prostate-specific antigen (PSA) in men who are at high risk for the disease. For the purpose of searching for potential prostate cancer symptoms, screening tests are used.

Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) (Epidemiology)

The likelihood of developing prostate cancer rises with age; it affects men most frequently between the ages of 65 and 74, with an average age of 67 at diagnosis. About 12% of men will develop prostate cancer in their lifetime. Prostate-specific antigen (PSA) screening has made it possible to identify and treat prostate cancer earlier. In 2000, there was a general decline in the incidence of prostate cancer. In 2008, when businesses started to discourage routine PSA screening, this rate started to fall. The rate decreased yearly by about 7% between 2011 and 2015. The incidence of low-risk prostate cancer was 37% lower between 2007 and 2013 than in 2004, according to a review of nearly 800,000 cases diagnosed between 2004 and 2013. However, the incidence of metastatic prostate cancer increased in these years, rising to 72.4% compared to 2004. Prostate cancer that had spread to other parts of the body was more common in men aged 55 to 69 (92%). 77% of prostate cancers are localized at the time of diagnosis. Regional lymph nodes were involved in 13% of cancer cases, and distant metastases were present in 6% of cases. For localized and regional prostate cancer, the 5-year survival rate is 100%, while for metastatic prostate cancer, it is 30%. Prostate cancer death rates among men of all racial and ethnic backgrounds have decreased since the early 1990s. Their share is still more than twice as high as that of Black people in any other group. Black men's prostate cancer not only has a higher incidence at diagnosis but also a tendency to be more aggressive and advanced, leading to advanced disease. Additionally, men with advanced cancer and men between the ages of 75 and 84 had higher death rates. In regions like Europe, Australia, Japan, and Russia, the number of men dying from prostate cancer is also rising.

Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) -Current Market Size & Forecast Trends

The market for resistant metastatic castration-resistant prostate cancer (mCRPC) is expected to experience robust growth, with a projected value of approximately USD 7.28 billion in 2024, anticipated to reach around USD 12.84 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.3% during this period. This growth is driven by the rising incidence of prostate cancer, particularly among aging populations, and advancements in treatment options, including new hormonal therapies, chemotherapy, and immunotherapies. Additionally, increasing awareness and early diagnosis are contributing to market expansion. The market is also expected to benefit from ongoing research and development efforts aimed at addressing the unmet needs in mCRPC treatment. Overall, the mCRPC market is well-positioned for substantial growth through 2035 as innovative therapies continue to emerge and improve patient outcomes.

In the past, androgen suppression has been a component of systemic therapy for metastatic and advanced prostate cancer. With this palliative therapy, the median progression-free survival and overall survival of metastatic disease are 18-20 months and 24-36 months, respectively. But drug-resistant hormone disease sets in for almost all patients. The inherent heterogeneity of prostate cancer and the inability of hormones to completely eradicate all prostate cancer clones, including androgen-dependent and androgen-independent components, limit the therapeutic potential of hormone therapy, despite the fact that it is associated with significant responses. Patients with clinically localized disease continue to have a high risk of extraprostatic disease of 30-60%, even though the incidence of newly diagnosed metastatic prostate cancer and microscopic lymph node metastases has decreased from 20% in the 1970s to 5% in 2013. Inferred from the prostate-specific antigen (PSA) level, pathological stage, and histological grade of the tumor, approx. 50% of prostate cancers with clinical localization will advance despite receiving the recommended initial treatment. The hormone dependence of prostate cancer may persist in some cases of hormone-resistant prostate cancer. It is currently impossible to predict whether these patients will benefit more from androgen deprivation than from ongoing hormone therapy. Advanced prostate cancer patients who haven't responded to all treatments might need supportive inpatient care for pain management. The treatment environment for patients with metastatic CRPC (mCRPC) has undergone a significant change in recent years as a result of the introduction of novel, highly effective therapies. This improvement in overall survival (OS) from 9 to 30 months as well as symptom-related benefits have occurred. Since 2002, there has been a steady improvement in the management of patients with mCRPC. In 2002, zoledronic acid treatment was shown to reduce the incidence of skeletal-related events (SREs); in 2004, the TAX 327 study demonstrated an improvement in overall survival (OS); and in 2015, the SWOG 9916 study demonstrated an extension of OS and progression-free survival (PFS) with docetaxel and mustin. Sipuleucel-T immunotherapy was authorized in the US in 2010. Treatment for long-term survivors is regulated by the Food and Drug Administration. A new tubulin class, cabazitaxel, demonstrated efficacy as second-line chemotherapy in 2011, while denosumab therapy increased the median time to first SRE. Abiraterone acetate and enzalutamide, two new hormonal medications, demonstrated further OS improvement as second-line therapies between 2011 and 2012. Due to its effectiveness in extending OS and delaying the onset of the first skeletal symptoms (SSE), radium-223, an alpha-emitting isotope of radium, became available for clinical use in 2013.

Report Highlights

Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Current Market Trends

Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Current & Forecasted Cases across the G8 Countries

Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Market Opportunities and Sales Potential for Agents

Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Patient-based Market Forecast to 2035

Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Untapped Business Opportunities

Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Product Positioning Vis-a-vis Competitors' Products

Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) - KOLs Insight